HRP20210283T1 - Stabilizirani pripravci alkilirajućih agensa i metode za njihovu upotrebu - Google Patents

Stabilizirani pripravci alkilirajućih agensa i metode za njihovu upotrebu Download PDF

Info

Publication number
HRP20210283T1
HRP20210283T1 HRP20210283TT HRP20210283T HRP20210283T1 HR P20210283 T1 HRP20210283 T1 HR P20210283T1 HR P20210283T T HRP20210283T T HR P20210283TT HR P20210283 T HRP20210283 T HR P20210283T HR P20210283 T1 HRP20210283 T1 HR P20210283T1
Authority
HR
Croatia
Prior art keywords
percent
weight
preparation
cutaneous
skin
Prior art date
Application number
HRP20210283TT
Other languages
English (en)
Inventor
Robert Alonso
Barry R. Walker
Peter A. Crooks
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of HRP20210283T1 publication Critical patent/HRP20210283T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/131Amines acyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (5)

1. Pripravak koji se sastoji od: 0.02 težinskih postotaka mekloretamin hidroklorida; 2.00 težinskih postotaka hidroksipropil celuloze; 0.01 težinskih postotaka dinatrijevog edetat dihidrata; 0.05 težinskih postotaka racemičnog mentola; 0.01 težinskih postotaka butiliranog hidroksitoulena; 49.91 težinskih postotaka 2-(2-etoksi-etoksi)etanola; 15.27 težinskih postotaka izopropilnog alkohola; 17.57 težinskih postotaka propilen glikola; 11.33 težinskih postotaka glicerina; 3.65 težinskih postotaka racemične mliječne kiseline; i 0.18 težinskih postotaka natrijevog klorida, za upotrebu kao lijek.
2. Pripravak prema patentnom zahtjevu 1 za upotrebu u lokalnom liječenju poremećaja kože.
3. Pripravak za upotrebu prema patentnom zahtjevu 2, naznačen time što je poremećaj kože izabran iz grupe koja se sastoji od psorijaze, ekcema, aktinične keratoze, lupusa, sarkoidoze, alopecije, kožnog T-staničnog limfoma (tj. mycosis fungoides), limforetikularne neoplazije, pleuralnog i peritonealnog izljeva, kožnog B-staničnog limfoma, pseudolimfoma kože, karcinoma skvamoznih stanica, karcinoma bazalnih stanica, bronhogenog karcinoma, malignog melanoma, limfosarkoma, kronične limfocitne leukemije, policitemije vere, limfomatoidne papuloze, Mucha-Habbermanove bolesti, vitiliga, i njihovih kombinacija.
4. Pripravak za upotrebu prema patentnom zahtjevu 3, naznačen time što je poremećaj kože vitiligo.
5. Pripravak za upotrebu prema patentnom zahtjevu 3, naznačen time što je poremećaj kože kožni T-stanični limfom (tj. mycosis fungoides).
HRP20210283TT 2008-03-27 2021-02-18 Stabilizirani pripravci alkilirajućih agensa i metode za njihovu upotrebu HRP20210283T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3984008P 2008-03-27 2008-03-27
EP18214529.2A EP3494960B1 (en) 2008-03-27 2009-03-11 Stabilized compositions of alkylating agents and methods of using same

Publications (1)

Publication Number Publication Date
HRP20210283T1 true HRP20210283T1 (hr) 2021-04-02

Family

ID=41114573

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20190551TT HRP20190551T1 (hr) 2008-03-27 2019-03-21 Stabilizirani pripravci alkilirajućih agensa i metode za njihovu upotrebu
HRP20210283TT HRP20210283T1 (hr) 2008-03-27 2021-02-18 Stabilizirani pripravci alkilirajućih agensa i metode za njihovu upotrebu

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20190551TT HRP20190551T1 (hr) 2008-03-27 2019-03-21 Stabilizirani pripravci alkilirajućih agensa i metode za njihovu upotrebu

Country Status (14)

Country Link
US (2) US8501817B2 (hr)
EP (2) EP3494960B1 (hr)
CN (2) CN107149591A (hr)
CY (2) CY1121777T1 (hr)
DK (1) DK3494960T3 (hr)
ES (2) ES2727523T3 (hr)
HR (2) HRP20190551T1 (hr)
HU (2) HUE043767T2 (hr)
LT (2) LT3494960T (hr)
PL (2) PL2273876T3 (hr)
PT (2) PT2273876T (hr)
SI (2) SI3494960T1 (hr)
TR (1) TR201907794T4 (hr)
WO (1) WO2009120493A2 (hr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110039943A1 (en) * 2005-03-14 2011-02-17 Robert Alonso Methods for treating skin disorders with topical nitrogen mustard compositions
US8501818B2 (en) * 2005-03-14 2013-08-06 Ceptaris Therapeutics, Inc. Stabilized compositions of alkylating agents and methods of using same
US7872050B2 (en) * 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
SI3494960T1 (sl) 2008-03-27 2021-04-30 Helsinn Healthcare Sa Stabilizirani sestavki alkilirajočih sredstev in metode uporabe le-teh
US20180125797A1 (en) * 2016-11-07 2018-05-10 Actelion Pharmaceuticals Ltd Methods for treating skin disorders with a topical composition of bis-(2-chloroethyl)methylamine

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4083692A (en) 1970-06-04 1978-04-11 The United States Of America As Represented By The Secretary Of The Army Detection and estimation of microquantities of alkylating agents
US3767792A (en) 1971-07-02 1973-10-23 Stanley Drug Products Inc Method for controlling the toxicity of drug products
US3904766A (en) 1973-06-19 1975-09-09 Scott Eugene J Van Treatment of psoriasis
US4206222A (en) * 1977-06-23 1980-06-03 Societe Civile Particuliere De Brevets Suffren Method for preparing a substance having properties against collagen diseases and products obtained
WO1987004154A1 (en) 1986-01-03 1987-07-16 The University Of Melbourne Melphalan derivatives
US4863910A (en) 1986-05-20 1989-09-05 Takeo Takayanagi Complexes of AZO compounds and/or their salts and an antitumor agent and a method for reducing the growth of tumors
US4725438A (en) * 1986-05-29 1988-02-16 Leazer Billie S Aloe vera ointment
IE60588B1 (en) * 1986-07-30 1994-07-27 Sumitomo Pharma Carbapenem compound in crystalline form, and its production and use
US5326790A (en) 1986-11-19 1994-07-05 Dermatologic Research Corporation Administration of skin medications by use of dicarboxylic acids and derivatives
US4853388A (en) 1987-05-15 1989-08-01 Pearlman Dale L Method for treating psoriasis with cytotoxic agents
US5051363A (en) 1987-06-26 1991-09-24 University Of Pennsylvania Method for modifying the toxicity of DNA reactive cross-linking agents to cells
US5229422A (en) 1987-09-07 1993-07-20 Teijin Limited Extemporaneous preparation type kit of a pharmaceutical substance-containing fat emulsion
GB8727157D0 (en) 1987-11-19 1987-12-23 Wellcome Found Pharmaceutical formulations
US4888354A (en) * 1987-12-21 1989-12-19 Theratech, Inc. Skin penetration enhancement using free base and acid addition salt combinations of active agents
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US4949641A (en) 1990-03-05 1990-08-21 The United States Of America As Represented By The Secretary Of The Army Method of safely detoxifying mustard gases
US6764681B2 (en) * 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US5820872A (en) 1992-11-18 1998-10-13 Yale University Methods and compositions for improving the effectiveness of X-irradiation therapy for the treatment of an internal solid tumor
EP0716589A4 (en) * 1993-07-23 1997-06-11 Morris Herstein COSMETIC COMPOSITION STIMULATING THE RENEWAL OF THE SKIN WITH A PROLONGED IRRITATION ELIMINATION EFFECT
FR2728166A1 (fr) * 1994-12-19 1996-06-21 Oreal Composition topique contenant un antagoniste de substance p
GB9501052D0 (en) * 1995-01-19 1995-03-08 Cancer Res Campaign Tech Improvements relating to prodrugs
US6551611B2 (en) * 1995-09-28 2003-04-22 Schering Aktiengesellschaft Hormone replacement therapy method
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US6124108A (en) 1996-05-15 2000-09-26 The United States Of America As Represented By The Secretary Of The Army Protein biomarker for mustard chemical injury
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
ATE326238T1 (de) 1996-06-27 2006-06-15 Chugai Pharmaceutical Co Ltd Mittel gegen myelome, welches zusammen mit antitumorwirkstoffen auf der basis von stickstoff-senfgasen verwendet werden kann
EP1024833A1 (en) * 1996-07-11 2000-08-09 Farmarc Nederland B.V. Pharmaceutical composition containing acid addition salt of basic drug
US6753155B1 (en) 1997-05-13 2004-06-22 The United States Of America As Represented By The Secretary Of The Army Protein biomarker for mustard chemical injury
EP1019034A2 (en) * 1997-07-01 2000-07-19 Atherogenics, Inc. Antioxidant enhancement of therapy for hyperproliferative conditions
AU760252B2 (en) * 1998-01-30 2003-05-08 Cold Spring Harbor Laboratory Modulation of cell proliferation, methods and reagents
GB9805868D0 (en) 1998-03-20 1998-05-13 Zeneca Ltd Anti-tumour agents
US6399678B2 (en) * 1998-06-25 2002-06-04 Tamko Roofing Products Silicone-aggregate mixtures for pumping and spraying applications
US20060079492A1 (en) * 1999-10-25 2006-04-13 Ahlem Clarence N Compositions and treatment methods
US6329148B1 (en) * 1999-02-16 2001-12-11 The Board Of Trustees Of The Leland Stanford University Combined therapy of diterpenoid triepoxides and death domain receptor ligands for synergistic killing of tumor cells
US6017902A (en) 1999-02-25 2000-01-25 Brookhaven Science Associates Boron containing amino acid compounds and methods for their use
US20020146692A1 (en) 2000-01-21 2002-10-10 Victoria Yamazaki Methods and materials relating to G protein-coupled receptor-like polypeptides and polynucleotides
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US20030215471A1 (en) * 2001-01-31 2003-11-20 Wilmott James M. Surfactant free topical compositions and method for rapid preparation thereof
US7547673B2 (en) * 2001-09-13 2009-06-16 The Johns Hopkins University Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production
WO2003094954A1 (en) 2001-09-25 2003-11-20 Quick Med Technologies, Inc. Composition and method for minimizing or avoiding adverse effects of vesicants
US20030082229A1 (en) 2001-11-01 2003-05-01 Board Of Regents, The University Of Texas Systems Parenteral chlorambucil for treatment of malignant and autoimmune disease and methods of use
CA2504665C (en) * 2002-11-12 2012-12-18 Jewish General Hospital Combination of a nitrogen mustard analogue and imatinib for the treatment of chronic lymphocytic leukemia
US8088605B2 (en) 2002-12-04 2012-01-03 Technologies Biolactics Inc. Exopolysaccharides delivery system for active molecules
US20050039228A1 (en) 2003-06-19 2005-02-17 The Samuel Roberts Noble Foundation Methods and compositions for analysis of plant gene function
WO2005007129A2 (en) 2003-07-17 2005-01-27 Angiotech International Ag Topical formulations with bioactive components
US20070287719A1 (en) * 2005-03-11 2007-12-13 Pfizer Inc Salts, Prodrugs and Formulations of 1-[5-(4-Amino-7-Isopropyl-7H-Pyrrolo[2,3-D]Pyrimidine-5-Carbonyl)-2-Methoxy-Phenyl]-3-(2,4-Dichloro-Phenyl)-Urea
US7872050B2 (en) * 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
US20110039943A1 (en) * 2005-03-14 2011-02-17 Robert Alonso Methods for treating skin disorders with topical nitrogen mustard compositions
US20060281720A1 (en) * 2005-06-08 2006-12-14 Loria Roger M 5-Androstenediol As An Inhibitor of Gliomas
SI3494960T1 (sl) * 2008-03-27 2021-04-30 Helsinn Healthcare Sa Stabilizirani sestavki alkilirajočih sredstev in metode uporabe le-teh

Also Published As

Publication number Publication date
PT3494960T (pt) 2021-02-09
CN107149591A (zh) 2017-09-12
CY1121777T1 (el) 2020-07-31
CY1123974T1 (el) 2022-05-27
WO2009120493A2 (en) 2009-10-01
TR201907794T4 (tr) 2019-06-21
PL3494960T3 (pl) 2021-05-17
ES2727523T3 (es) 2019-10-16
HUE053482T2 (hu) 2021-06-28
US8501817B2 (en) 2013-08-06
LT2273876T (lt) 2019-05-27
ES2848841T3 (es) 2021-08-12
CN102036557A (zh) 2011-04-27
EP2273876A4 (en) 2013-10-23
WO2009120493A3 (en) 2010-03-04
EP3494960B1 (en) 2020-11-25
US20100029783A9 (en) 2010-02-04
SI2273876T1 (sl) 2019-09-30
EP2273876A2 (en) 2011-01-19
EP2273876B1 (en) 2019-03-06
EP3494960A1 (en) 2019-06-12
US20140142193A1 (en) 2014-05-22
US20090247645A1 (en) 2009-10-01
LT3494960T (lt) 2021-02-25
DK3494960T3 (da) 2021-01-25
HRP20190551T1 (hr) 2019-05-03
HUE043767T2 (hu) 2019-09-30
SI3494960T1 (sl) 2021-04-30
PL2273876T3 (pl) 2019-09-30
PT2273876T (pt) 2019-06-04

Similar Documents

Publication Publication Date Title
HRP20210283T1 (hr) Stabilizirani pripravci alkilirajućih agensa i metode za njihovu upotrebu
PE20210667A1 (es) Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1
NI201900039A (es) Derivados de 6, 7, 8, 9-tetrahidro-3h-pirazolo[4, 3-f] isoquinolina útiles en el tratamiento del cáncer
NZ599001A (en) compositions comprising bis(2-chloroethyl)methylamine (mechlorethamine)
NZ702571A (en) 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
ECSP11011560A (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
DOP2012000225A (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
UY31272A1 (es) Nuevos derivados de ácido azabifenilaminobenzoico
UY31294A1 (es) Derivados de tetrahidrocarbozol, métodos para obtenerlos, formulaciones que los contienen y usos de los mismos
GT201300266A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
ECSP109935A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k
AR084691A1 (es) Formulacion de uso topico para un inhibidor de jak y metodo para tratar trastorno de la piel
BR112014014341A2 (pt) Intermediário metilado, seu método de preparação e seus usos, e composição farmacêutica
BR112014032809A8 (pt) urolitinas, usos de uma quantidade eficaz de uma urolitina ou um sal farmaceuticamente aceitável da mesma e composição compreendendo as mesmas
UY31124A1 (es) Derivados de oxiadazol y su uso como potenciadores del receptor metabotropico de glutamato - 842
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
PH12015500063A1 (en) Azaindole derivatives which act as pi3k inhibitors
EA201100358A1 (ru) Дабигатран для чрескожной хирургической катетеризации сердца
CO6361924A2 (es) Nuevas lactamas como inhibidores de beta secretasa
BR112014016661A8 (pt) formulação de liberação prolongada para reduzir a frequência de urinação e método de uso da mesma
BR112013033568A2 (pt) compostos éter amidopiridil e composições e seu uso contra parasitas
BR112014001083B8 (pt) Composto, processo para a preparação de um composto, composição farmacêutica, uso da composiçâo farmacêutica e uso do composto
UY31672A1 (es) "agonistas de receptores muscarínicos composiciones farmacéuticas métodos de tratamiento de los mismos, y procedimientos para su preparación"
UY31839A (es) Compuestos